胃肠胰神经内分泌肿瘤（GEP-NEN）数据表

数据集获取（Figshare）

• 源站标题：GEP-NENdatasheet.
• DOI：10.1371/journal.pone.0325727.s003
• 发布日期：2025-08-06
• 文件数：1 个
• 文件总体积：15.86 KB
• 源站页面：https://plos.figshare.com/articles/dataset/GEP-NENdatasheet_/29845945

命令行下载

curl -L -o "pone.0325727.s003.xlsx" "https://ndownloader.figshare.com/files/56973328"

文件清单

• pone.0325727.s003.xlsx（15.86 KB）

文件总体积 15.86 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Introduction
Comprehensive genomic profiling (CGP) is increasingly being integrated into standard clinical practice as a strategy to guide subsequent treatment decisions by identifying novel therapeutic options based on tumor-specific mutations. However, its clinical utility in neuroendocrine neoplasms (NENs) remains to be determined. We conducted a cross-sectional analysis of genomic alterations, including tumor mutational burden (TMB) and microsatellite instability (MSI), in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), comparing neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs).
Results
CGP was performed on 50 patients with advanced GEP-NENs between August 2017 and October 2023. Of these, 38 were diagnosed with NETs and 12 with NECs. Primary tumor sites included the pancreas (n = 24), gastrointestinal tract (n = 25), and one case of unknown origin. In our study, CGP analysis comparing NETs and NECs documented different genetic profiles. In addition, median TMB was significantly higher in NECs (5.0 vs. 1.9 mutations/megabase; p = 0.0101). High TMB was identified in 4 of 12 NECs (33.3%) and in only 1 of 38 NETs (2.6%) (p = 0.0093). NECs also harbored a significantly greater number of mutations per case than NETs (5.5 vs. 2.0; p = 0.0014). Actionable mutations were identified in 18 of 50 patients, and 7 patients received mutation-guided therapy: 2 with NETs and 5 with NECs. The frequency of treatment initiation based on CGP findings was significantly higher in patients with NECs (p = 0.0059).
Conclusions
NECs are genetically distinct from NETs, with a higher prevalence of actionable mutations and greater therapeutic relevance of CGP findings. These results suggest that CGP may be particularly valuable in NECs, where therapeutic options are limited, supporting its proactive implementation in this subgroup.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0325727.s003（source: https://plos.figshare.com/articles/dataset/GEP-NENdatasheet_/29845945）。